Isavuconazole: Difference between revisions
From IDWiki
Content deleted Content added
No edit summary |
|||
| Line 10: | Line 10: | ||
*Indications include {{#ask: [[Is treated by::isavuconazole]]}} |
*Indications include {{#ask: [[Is treated by::isavuconazole]]}} |
||
=== Breakpoints === |
|||
{| class="wikitable" |
|||
! rowspan="2" |Species |
|||
! rowspan="2" |ECOFF (mg/L) |
|||
! colspan="4" |Breakpoints (μg/mL) |
|||
! colspan="4" |Breakpoints (mm) |
|||
|- |
|||
! S |
|||
!I |
|||
!SDD |
|||
!R |
|||
!S |
|||
! I |
|||
!SDD |
|||
!R |
|||
|- |
|||
|[[Candida albicans]] |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
|[[Candida glabrata]] |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
|[[Candida krusei]] |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
|[[Candida parapsilosis]] |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
|[[Candida tropicalis]] |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
|[[Cryptococcus neoformans]] |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
|[[Cryptococcus gattii]] |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
| |
|||
|- |
|||
|[[Aspergillus flavus]] |
|||
|2 |
|||
|— |
|||
| colspan="2" rowspan="5" | |
|||
|— |
|||
| colspan="4" rowspan="5" | |
|||
|- |
|||
|[[Aspergillus fumigatus]] |
|||
|2 |
|||
|≤1 |
|||
|>1 |
|||
|- |
|||
|[[Aspergillus nidulans]] |
|||
|0.25 |
|||
|≤0.25 |
|||
|>0.25 |
|||
|- |
|||
|[[Aspergillus niger]] |
|||
|4 |
|||
|— |
|||
|— |
|||
|- |
|||
|[[Aspergillus terreus]] |
|||
|1 |
|||
|≤1 |
|||
|>1 |
|||
|} |
|||
==Dosing== |
==Dosing== |
||
Revision as of 13:03, 22 October 2024
Background
Mechanism of Action
- Azole antifungal that inhibits lanosterol 14-α demethylase in the peptidoglycan synthesis pathway
Spectrum of Activity
- Active against Candida, Cryptococcus, Aspergillus including Aspergillus flavus, Aspergillus fumigatus, and Aspergillus niger, and Mucorales
- Indications include Chromoblastomycosis, Cladophialophora, Coccidioides immitis
Breakpoints
| Species | ECOFF (mg/L) | Breakpoints (μg/mL) | Breakpoints (mm) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| S | I | SDD | R | S | I | SDD | R | ||
| Candida albicans | |||||||||
| Candida glabrata | |||||||||
| Candida krusei | |||||||||
| Candida parapsilosis | |||||||||
| Candida tropicalis | |||||||||
| Cryptococcus neoformans | |||||||||
| Cryptococcus gattii | |||||||||
| Aspergillus flavus | 2 | — | — | ||||||
| Aspergillus fumigatus | 2 | ≤1 | >1 | ||||||
| Aspergillus nidulans | 0.25 | ≤0.25 | >0.25 | ||||||
| Aspergillus niger | 4 | — | — | ||||||
| Aspergillus terreus | 1 | ≤1 | >1 | ||||||
Dosing
- Isavuconazole 200 mg IV tid for 6 doses followed by 200 mg IV daily
Renal Dosing
- No adjustment needed
Hepatic Dosing
- No adjustment needed
Safety
Adverse Drug Reactions
- Nausea, vomiting, diarrhea
- Elevated liver enzymes
- Generally transient ALT elevation that does not require change in therapy
- May also include severe cholestatic or hepatocellular enzyme rises within the first few months of therapy
- See also LiverTox
- Hypokalemia
Drug-Drug Interactions
- Increases levels of sirolimus and tacrolimus
- Increases levels of cyclosporine
- Contraindicated with carbamazepine
